
Zhen-ming Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6699059/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study. European Journal of Medicinal Chemistry, 2022, 233, 114196.	5.5	4
2	The state of the art of PROTAC technologies for drug discovery. European Journal of Medicinal Chemistry, 2022, 235, 114290.	5.5	45
3	Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain. European Journal of Medicinal Chemistry, 2022, 237, 114413.	5.5	5
4	CMNPD: a comprehensive marine natural products database towards facilitating drug discovery from the ocean. Nucleic Acids Research, 2021, 49, D509-D515.	14.5	105
5	Discovery of 4-arylthiophene-3-carboxylic acid as inhibitor of ANO1 and its effect as analgesic agent. Acta Pharmaceutica Sinica B, 2021, 11, 1947-1964.	12.0	13
6	The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo. Journal of Medicinal Chemistry, 2021, 64, 3976-3996.	6.4	16
7	Target Prediction Model for Natural Products Using Transfer Learning. International Journal of Molecular Sciences, 2021, 22, 4632.	4.1	9
8	Discovery of Novel and Potent <i>N</i> -Methyl- <scp>d</scp> -aspartate Receptor Positive Allosteric Modulators with Antidepressant-like Activity in Rodent Models. Journal of Medicinal Chemistry, 2021, 64, 5551-5576.	6.4	12
9	Chemical Space, Scaffolds, and Halogenated Compounds of CMNPD: A Comprehensive Chemoinformatic Analysis. Journal of Chemical Information and Modeling, 2021, 61, 3323-3336.	5.4	4
10	Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer. European Journal of Medicinal Chemistry, 2021, 218, 113386.	5.5	29
11	AIScaffold: A Web-Based Tool for Scaffold Diversification Using Deep Learning. Journal of Chemical Information and Modeling, 2021, 61, 1-6.	5.4	8
12	DeepScaffold: A Comprehensive Tool for Scaffold-Based De Novo Drug Discovery Using Deep Learning. Journal of Chemical Information and Modeling, 2020, 60, 77-91.	5.4	84
13	Medicinal chemistry perspective of TRPM2 channel inhibitors: where we are and where we might be heading?. Drug Discovery Today, 2020, 25, 2326-2334.	6.4	10
14	TF3P: Three-Dimensional Force Fields Fingerprint Learned by Deep Capsular Network. Journal of Chemical Information and Modeling, 2020, 60, 2754-2765.	5.4	9
15	Privileged Scaffold Analysis of Natural Products with Deep Learningâ€based Indication Prediction Model. Molecular Informatics, 2020, 39, e2000057.	2.5	10
16	Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors. European Journal of Medicinal Chemistry, 2020, 201, 112445.	5.5	17
17	Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. Journal of Chemical Information and Modeling, 2020, 60, 1202-1214.	5.4	7
18	Functional Characterization and Structural Basis of an Efficient Di- <i>C</i> -glycosyltransferase from <i>Glycyrrhiza glabra</i> . Journal of the American Chemical Society, 2020, 142, 3506-3512.	13.7	76

ZHEN-MING LIU

#	ARTICLE	IF	CITATIONS
19	Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2019, 62, 6645-6664.	6.4	38
20	Direct Gating of the TRPM2 Channel by cADPR via Specific Interactions with the ADPR Binding Pocket. Cell Reports, 2019, 27, 3684-3695.e4.	6.4	45
21	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry, 2019, 171, 221-234.	5.5	19
22	Graph-based generative models for de Novo drug design. Drug Discovery Today: Technologies, 2019, 32-33, 45-53.	4.0	15
23	Unravel a neuroactive sHA sulfation pattern with neurogenesis activity by a library of defined oligosaccharides. European Journal of Medicinal Chemistry, 2019, 163, 583-596.	5.5	8
24	Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 235-252.	5.5	29
25	Discovery of new GSK-3 \hat{l}^2 inhibitors through structure-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 160-166.	2.2	19
26	Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening. PLoS ONE, 2018, 13, e0205175.	2.5	16
27	Multi-objective de novo drug design with conditional graph generative model. Journal of Cheminformatics, 2018, 10, 33.	6.1	193
28	Identification of the ADPR binding pocket in the NUDT9 homology domain of TRPM2. Journal of General Physiology, 2017, 149, 219-235.	1.9	49
29	An Unbiased Method To Build Benchmarking Sets for Ligand-Based Virtual Screening and its	5.4	46